Chronic myeloid leukemia (CML) is caused by the formation of the BCR-ABL fusion protein as a result of the t(9;22) chromosomal translocation. The elucidation of its molecular pathogenesis led to the identification of a therapeutic target and the subsequent synthesis and introduction of a small-molecule inhibitor for this target, imatinib. Because CML is the first disease successfully treated by targeted kinase inhibition, it served as a paradigm for discovery of disease mechanism and drug development in other diseases in which constitutive kinase expression plays a central role in pathogenesis. Despite the spectacular success of imatinib, not all CML patients derive great benefit from it. This review will cover some of the currently known p...
Imatinib was the first signal transduction inhibitor (STI), used in a clinical setting. It prevents ...
The discovery of tyrosine kinases that, once deregulated, can cause malignancy, allowed the developm...
Chronic myeloid leukaemia (CML) is a molecularly defined disease. The BCR-ABL fusion occurs in all c...
Chronic myeloid leukemia (CML) was the first type of cancer in humans to be linked to a single, acqu...
The deregulated activity of BCR-ABL tyrosine kinase originating from the t(9;22) chromosomal translo...
Deregulated activity of BCR-ABL1, a nonreceptor tyrosine kinase encoded by the fusion gene resulting...
The tyrosine kinase inhibitor imatinib mesylate (IM) has proved a major advance in the management of...
BCR-ABL1 represents a driving force in the biology of CML cell as demonstrated by the spectacular re...
Ila Tamascar, Jeyanthi RamanarayananDepartment of Medical Oncology, Roswell Park Cancer Institute, E...
Chronic myeloid leukemia (CML) is the first human malignancy for which the promise of targeted thera...
Chronic myeloid leukaemia (CML) is a clonal disorder of the haemopoietic stem cell arising as a cons...
Chronic myelogenous leukaemia (CML) is characterised by a t(9;22)(q34;q11) translocation, which prod...
Chronic myelogenous leukaemia (CML) is characterised by a t(9;22)(q34;q11) translocation, which prod...
Throughout its history, chronic myeloid leukemia (CML) has set precedents for cancer research and th...
Chronic myeloid leukemia (CML) is a poor prognostic disease which is characterized by Philadelphia c...
Imatinib was the first signal transduction inhibitor (STI), used in a clinical setting. It prevents ...
The discovery of tyrosine kinases that, once deregulated, can cause malignancy, allowed the developm...
Chronic myeloid leukaemia (CML) is a molecularly defined disease. The BCR-ABL fusion occurs in all c...
Chronic myeloid leukemia (CML) was the first type of cancer in humans to be linked to a single, acqu...
The deregulated activity of BCR-ABL tyrosine kinase originating from the t(9;22) chromosomal translo...
Deregulated activity of BCR-ABL1, a nonreceptor tyrosine kinase encoded by the fusion gene resulting...
The tyrosine kinase inhibitor imatinib mesylate (IM) has proved a major advance in the management of...
BCR-ABL1 represents a driving force in the biology of CML cell as demonstrated by the spectacular re...
Ila Tamascar, Jeyanthi RamanarayananDepartment of Medical Oncology, Roswell Park Cancer Institute, E...
Chronic myeloid leukemia (CML) is the first human malignancy for which the promise of targeted thera...
Chronic myeloid leukaemia (CML) is a clonal disorder of the haemopoietic stem cell arising as a cons...
Chronic myelogenous leukaemia (CML) is characterised by a t(9;22)(q34;q11) translocation, which prod...
Chronic myelogenous leukaemia (CML) is characterised by a t(9;22)(q34;q11) translocation, which prod...
Throughout its history, chronic myeloid leukemia (CML) has set precedents for cancer research and th...
Chronic myeloid leukemia (CML) is a poor prognostic disease which is characterized by Philadelphia c...
Imatinib was the first signal transduction inhibitor (STI), used in a clinical setting. It prevents ...
The discovery of tyrosine kinases that, once deregulated, can cause malignancy, allowed the developm...
Chronic myeloid leukaemia (CML) is a molecularly defined disease. The BCR-ABL fusion occurs in all c...